- Home
- LUMO vs CLGN Comparison
LUMO vs CLGN Comparison
Compare LUMO & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUMO
- CLGN
- Stock Information
- Founded
- LUMO 2011
- CLGN 2004
- Country
- LUMO United States
- CLGN Israel
- Employees
- LUMO N/A
- CLGN N/A
- Industry
- LUMO Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- LUMO Health Care
- CLGN Health Care
- Exchange
- LUMO Nasdaq
- CLGN Nasdaq
- Market Cap
- LUMO 37.7M
- CLGN 44.1M
- IPO Year
- LUMO N/A
- CLGN N/A
- Fundamental
- Price
- LUMO $4.33
- CLGN $4.29
- Analyst Decision
- LUMO Buy
- CLGN Strong Buy
- Analyst Count
- LUMO 4
- CLGN 2
- Target Price
- LUMO $9.38
- CLGN $12.50
- AVG Volume (30 Days)
- LUMO 126.3K
- CLGN 17.8K
- Earning Date
- LUMO 11-07-2024
- CLGN 11-27-2024
- Dividend Yield
- LUMO N/A
- CLGN N/A
- EPS Growth
- LUMO N/A
- CLGN N/A
- EPS
- LUMO N/A
- CLGN N/A
- Revenue
- LUMO $2,205,000.00
- CLGN $689,000.00
- Revenue This Year
- LUMO $184.11
- CLGN N/A
- Revenue Next Year
- LUMO N/A
- CLGN $670.03
- P/E Ratio
- LUMO N/A
- CLGN N/A
- Revenue Growth
- LUMO 300.59
- CLGN N/A
- 52 Week Low
- LUMO $1.37
- CLGN $3.61
- 52 Week High
- LUMO $4.58
- CLGN $6.99
- Technical
- Relative Strength Index (RSI)
- LUMO 56.58
- CLGN 54.40
- Support Level
- LUMO $4.25
- CLGN $3.61
- Resistance Level
- LUMO $4.44
- CLGN $4.58
- Average True Range (ATR)
- LUMO 0.12
- CLGN 0.23
- MACD
- LUMO -0.03
- CLGN 0.09
- Stochastic Oscillator
- LUMO 33.33
- CLGN 69.59
About LUMO Lumos Pharma Inc.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.